Ketalar (Ketamine)

Ketamine blocks the NMDA receptor, a key component of excitatory neurotransmission, leading to dissociative anesthesia. Its additional actions on opioid receptors, monoamine pathways, and calcium channels contribute to analgesic effects and, at sub‑anesthetic doses, to rapid antidepressant responses.

The dose of Ketalar is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and the intended route (intravenous or intramuscular). Specific dosing regimens are individualized and should follow institutional protocols and the prescriber’s judgment.

Ketamine crosses the placenta and is excreted in breast milk, so its safety in pregnancy and lactation has not been fully established. Use is generally reserved for situations where the potential benefit outweighs potential risks, and it should be prescribed only after careful risk assessment by a qualified healthcare professional.

To order Ketalar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including cold‑chain handling if required) and assists with import documentation.

Ketalar differs from traditional inhalational or opioid‑based anesthetics by providing dissociative anesthesia through NMDA antagonism, which results in rapid onset and preservation of airway reflexes at sub‑anesthetic doses. Compared with agents like propofol, ketamine maintains cardiovascular stability but may produce psychotomimetic side effects that require monitoring.

Ketalar should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use, and discard any solution that appears discolored or contains particles.

Ketalar is supplied as an injectable solution and can be given intravenously or intramuscularly. Administration is performed by qualified healthcare professionals in a controlled environment, with dosing titrated to achieve the desired depth of anesthesia or sedation while continuously monitoring vital signs.

The most serious risks include respiratory depression, severe hypertension, and psychotomimetic reactions such as hallucinations or agitation. Cardiac arrhythmias may also occur, especially in patients with pre‑existing heart disease. Immediate medical intervention and airway support are essential if these events arise.

Ketalar is contraindicated in patients with known hypersensitivity to ketamine or any component of the formulation. It should be avoided in individuals with uncontrolled severe hypertension, recent myocardial infarction, severe heart failure, or active psychosis, unless the benefits clearly outweigh the risks and appropriate monitoring is available.